Stanford University Lands NIH Grant to Fund U.S. Phase II Trial of tiakis Biotech’s Elafin (Tiprelestat) in Pulmonary Arterial Hypertension
– Presenting a new, disease-modifying therapeutic approach for Pulmonary Arterial Hypertension (PAH), a rare disease with substantial unmet medical requirements Kiel, GERMANY, September 8, 2025 – tiakis Biotech, a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for severe pulmonary
More